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Summary
 Background Concomitant chemoradiation is a widely used therapeutic concept in intensiﬁ ed 
locoregional treatment of high risk head and neck cancer patients. In this con-
text, cisplatin monotherapy or in combination with other chemotherapeutics is 
recognized as the most effective drug to be added to radiotherapy.
 Aim The aim of this review is to present the rationale for combining radiotherapy with 
cisplatin in the treatment of head and neck cancer and to summarize the expe-
rience of the Institute of Oncology Ljubljana, Slovenia, gained through two pro-
spective randomized trials on chemoradiation with mitomycin C and bleomycin 
in operable as well as inoperable head and neck cancer patients. Furthermore, 
recent developments in technology and biological drug modeling are discussed, 
which are considered to have a potential to add signiﬁ cantly to the locoregional 
effectiveness of radiotherapy.
 Materials/Methods References were retrieved using the online data base of the National Library of 
Medicine (PubMed: http://www.ncbi.nlm.nih.gov/PubMed). Terms used included: 
head and neck carcinoma, squamous cell carcinoma, concomitant chemoradi-
otherapy, cisplatin, mitomycin C, bleomycin. The results of studies using cispla-
tin-based chemoradiation regimens in the treatment of patients with inoperable 
tumors and on postoperative stetting were compared with the results of the stud-
ies, conducted at the Institute of Oncology and ENT Department at the Clinical 
Center Ljubljana, Slovenia.
 Results When comparing mitomycin C-bleomycin chemotherapy with other comparable 
series on exclusively inoperable oropharyngeal cancer, but with cisplatin (or car-
boplatin) and 5-ﬂ uorouracil chemotherapy, and to standard dose cisplatin regi-
men used in postoperative setting, the effectiveness of our unconventional drug 
combination appeared to be at least equivalent to the well established platinum-
based chemotherapy standard.
 Conclusions At the moment, concomitant chemoradiation with cisplatin-based chemotherapy 
is the most widely used way for potentiation of locoregional effect of radiothera-
py in high risk head and neck cancer patients. Our clinical experiences with mi-
tomycin C and bleomycin chemoradiation showed that there was still a window of 
opportunity to achieve equivalent clinical results with other drug combinations.
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BACKGROUND
Head and neck cancer is the sixth most prevalent 
cancer worldwide, with a global yearly incidence of 
more than 500,000, representing approximately 5% 
of all cancers [1]. Although early tumours are po-
tentially curable with surgery and chemotherapy, 
the prognosis of patients with advanced disease has 
remained poor. Because the majority of randomized 
trials on induction chemotherapy failed to prove 
any survival beneﬁ t in this poor prognosis group of 
patients, research has focused on the concurrent 
use of chemotherapy and irradiation [2].
The concept of concurrent application of chem-
otherapy and irradiation has been investigated 
since the 1960s [2]. The main rationale for such 
treatment is to increase local control by over-
coming radioresistance and to eradicate system-
ic micrometastases. Another important aim of 
combining chemotherapy and radiotherapy is to 
preserve the function and cosmesis of treated or-
gans, which could be severely deteriorated by us-
ing extensive and mutilating surgery as the only 
therapy or part of the treatment package.
The most signiﬁ cant potential mechanisms of in-
teraction between chemotherapy and radiothera-
py are: (i) to increase the steepness of the dose-re-
sponse curve or to shift the curve to the left; (ii) to 
inhibit the repair of radiotherapy-induced suble-
thal or potentially lethal damage; (iii) to improve 
tumour oxygenation; (iv) to provide selective cyto-
toxicity for hypoxic cells or radiosensitization of hy-
poxic cells; and (v) to increase apoptosis [2,3].
Initially, radiotherapy was combined with agents 
like methotrexate, hydroxyurea, ﬂ uorouracil or 
bleomycin. In addition to systemic toxicity, each 
of these drugs also induces inﬂ ammation of oral, 
pharyngeal and laryngeal mucosa. Consequently, 
the local side-effects of irradiation are intensiﬁ ed, 
which results in poor patient compliance and pro-
longation of therapy. No improvement in overall 
survival when compared with irradiation alone 
was observed in clinical trials [2].
The ﬁ rst breakthrough in chemoradiation of head 
and neck carcinoma was the introduction of cispla-
tin to clinical practice in the early 1970s. Nowadays, 
cisplatin is used in a variety of treatment schedules 
and, at the moment, it is considered a standard 
drug in concomitant chemoradiation protocols. It 
is the best characterized currently available radio-
sensitizer and possesses all the mechanisms of in-
teraction with irradiation summarized above [3]. 
A cisplatin dose of 100mg/m2 administered in 3-
week intervals, concomitantly with radiotherapy, 
is considered as a standard. In this respect, it is im-
portant to take into account the observation from 
several clinical studies suggesting that a cumulative 
cisplatin dose of approximately 200mg/m2, inde-
pendent of treatment schedule, might be sufﬁ cient 
to yield a beneﬁ cial anti-tumour effect. Lower but 
still effective cisplatin doses, applied on a weekly 
or daily basis, should result in a more favourable 
toxicity proﬁ le and better compliance with com-
bined therapy [4].
WHY CISPLATIN?
There are numerous combinations of various 
drugs that have been tested in clinical trials such 
as (i) carboplatin – a second-generation platinum 
drug, mimicking the radiopotentiation proper-
ties of cisplatin with a somewhat different tox-
ic proﬁ le [3]; (ii) mitomycin C – a bioreductive 
alkylating agent, activated enzymatically under 
hypoxic conditions and selectively toxic for hy-
poxic cells, but not for well oxygenated cells in 
tumour surrounding [5]; (iii) taxanes – antimi-
totic agent that promote tubulin polymerization 
and the formation of stable microtubules [6]; 
(iv) gemcitabine – a nucleoside analogue with 
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the ability to inhibit DNA replication and repair 
[6]; and many others. However, following abun-
dant clinical experience gained over decades, cis-
platin monotherapy or in combination with oth-
er chemotherapeutics has become the drug of 
choice in the majority of concomitant chemora-
diation protocols [4].
The most convincing evidence of the effec-
tiveness of concurrent chemoradiotherapy in 
non-metastatic squamous cell carcinoma of the 
head and neck and of the central role of cispla-
tin in the chemotherapy part of these protocols 
was provided by the MACH-NC meta-analysis in 
2000 and its update in 2004. In this meta-analysis, 
individual patient data from 63 randomized trials 
with more than 10,000 participants with locally ad-
vanced non-metastatic squamous cell carcinoma 
of the head and neck, conducted between 1965 
and 1993, were analyzed. The treatment results 
of the study arms with or without chemotherapy 
were compared, and chemotherapy (irrespective 
of type) was found to add signiﬁ cantly to locore-
gional treatment. The analysis yielded a pooled 
hazard ratio of death of 0.90, corresponding to 
an absolute survival beneﬁ t of 4% at 5 years in fa-
vour of the chemoradiotherapy arm. Analyzing 
the trials by the type of chemotherapy, a survival 
advantage was recorded only in the group of 26 
concomitant trials with altogether 3727 patients 
with an absolute 5-year survival beneﬁ t of 8% at 
5 years and 19% reduction of the risk of death. 
Unfortunately, heterogeneity between trials and, 
consequently, of the results, prevents a ﬁ rm con-
clusion on the extent of the beneﬁ t of concom-
itantly applied chemotherapy. There was no sig-
niﬁ cant beneﬁ t associated with the application of 
adjuvant or neoadjuvant chemotherapy [7].
In an update of the MACH-HN database, 24 trials 
were additionally included, most of them testing 
concomitant chemoradiation. Altogether, 87 trials 
with individual data on more than 16,000 patients 
treated between 1965 and 2000 were analyzed, re-
conﬁ rming the overall beneﬁ t of adding chemo-
therapy to radiotherapy. Also, in the group of 50 
concomitant trials, the results were identical when 
comparing the 1965–1993 trials and 1994–2000 
trials in the deﬁ nitive and postoperative setting, 
but without signiﬁ cant heterogeneity in the re-
cent group. The beneﬁ t was most pronounced 
and was signiﬁ cantly higher for platinum-based 
chemotherapy, applied as monochemotherapy 
or in combination with other drugs, compared 
to other chemotherapy regimens [8].
EXPERIENCE OF THE INSTITUTE OF ONCOLOGY, 
LJUBLJANA, SLOVENIA
At the Institute of Oncology, Ljubljana, and the 
ENT Department at the Clinical Centre Ljubljana, 
Slovenia, we conducted two prospective rand-
omized trials to assess the efﬁ cacy and toxici-
ty of simultaneous application of irradiation , 
RADIOTHERAPY
2Gy/ fx, fx/day*, 5 fx/week
Week 1
Mitomycin C, 15mg/m2 IV
Bleomycin , 15mg IM (twice/week)
Suplement drugs:
– Dicumarol, 300mg po (on evening and morning before mitomycin C application)
– Chlorpromazine, 200mg po (administered together with bleomycin)
– Nicotinamide, 650mg po (on daily basis)
* At 10Gy (i.e. on the 5th day of radiotherapy course) when the first dose of mitomycin C was applied, patients were irradiated twice with
   the interfraction interval of ≥6 hours.
Mitomycin C, 10mg/m2 IV
Week 2 Week 3 Week 4 Week 5 Week 6 Week 7
Figure 1. Concomitant chemoradiotherapy with mitomycin C and bleomycin – basic treatment schedule. In the study on postoperative 
chemoradiation, basic chemotherapy prescriptions and radiotherapy dose levels were changed as described in the text.
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mitomycin C and bleomycin in the treatment of 
patients with inoperable tumours and on post-
operative setting . Radiotherapy regimen and 
chemotherapy schedule were the same in both 
studies.
Rationale for selection of chemotherapy 
schedule
Mitomycin C and bleomycin were selected to be 
administered with radiotherapy on the basis of 
their biochemical and pharmacological properties 
(Figure 1). Conventional fractionation with 2Gy 
daily dose delivered ﬁ ve times per week and 2.5-D 
treatment planning were used in both studies.
In advanced head and neck tumours, a high pro-
portion of hypoxic cells can be expected, whereas 
mechanical perturbation of tissues during surgery 
gives rise to the formation of hypoxic islands in-
side the area of the operative bed. Consequently, 
the alkylating agent mitomycin C was selected due 
to its selective toxicity to hypoxic cells. Under 
hypoxic conditions, it is reductively activated by 
a number of oxidoreductases and, in combina-
tion with irradiation, enhances the cytodestruc-
tive effect of the latter [5]. Originally, 15mg/m2 
I.V. mitomycin C application was planned at 10Gy 
of radiotherapy, when the proportion of radiore-
sistant hypoxic cells was believed to be the great-
est, and the mitomycin C dose of 10mg/m2 was to 
be given on the last day of radiotherapy [9,10]. 
Because more than only an additive effect of the 
drug was expected, the patients received a dou-
ble dose of irradiation on the day of its ﬁ rst ap-
plication [11]. Later on, in a postoperative set-
ting, the second dose of mitomycin C was omitted 
[12,13]. To increase the effectiveness of mitomy-
cin C on hypoxic cells, 300mg of dicumarol was 
applied orally in the evening and morning be-
fore mitomycin C administration [14].
To the contrary, bleomycin prevailingly acts on 
oxygenated cells. To minimize its toxicity and to 
achieve protracted resorption, a low dose inten-
sity (5 mg twice a week) and I.M. way of applica-
tion were selected [15]. To further reduce the 
risk of bleomycin-related pulmonary toxicity and 
to enhance its effect on tumour cells, 200mg of 
chlorpromazine was administered orally togeth-
er with bleomycin [16], whereas 650mg of oral 
nicotinamide was given on a daily basis through-
out the duration of therapy to avoid the emer-
gence of tumour cell lines resistant to bleomy-
cin [17]. These prescriptions were changed in 
the study on postoperative chemoradiation to 
75mg of chlorpromazine and to 225mg of nico-
tinamide.
Clinical results
Inoperable tumours
Between 1991 and 1993, 64 patients with inopera-
ble tumours, 94% of them with UICC TNM stage 
IV tumours, were randomly assigned to the ra-
diotherapy arm (RT, 32 patients) and combined 
radiochemotherapy arm (CRT, 32 patients). The 
survival results were the same in the preliminary 
[10] as well as ﬁ nal report [11]. A statistical-
ly highly signiﬁ cant difference in favour of the 
combined treatment arm was observed in the tu-
mour remission rate 2 months after the end of 
therapy (59% vs. 31%, P= 0.04) and the 4-year dis-
ease-free survival (37% vs. 8%, P=0.01), whereas 
in the overall survival, only a trend was observed 
(26% vs. 7%, P=0.08). However, when only the 
patients with oropharyngeal cancer were con-
sidered (64% of all patients), the difference be-
tween the two arms was even more pronounced 
and reached the level of statistical signiﬁ cance 
in all three study endpoints [11].
The signiﬁ cance of these results prompted us to 
stop the study prematurely and, after December 
1993, mitomycin C-bleomycin chemoradiothera-
py became the standard treatment at our institute 
for all eligible patients with inoperable oropha-
ryngeal carcinoma. In the long term (median 
follow-up time of 85 months), in the cohort of 
the ﬁ rst 95 consecutive patients with inoperable 
oropharyngeal tumours, 78% of them had stage 
IV disease, the probability of locoregional control 
at 5 years was 55%, the disease-free survival 51%, 
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Figure 2. Survival of patients with inoperable oropharyngeal 
cancer (N=95) treated with concomitant chemoradiotherapy with 
mitomycin C and bleomycin: impact of treatment intensity.
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and the overall survival 32% [18]. In a multivar-
iate model, the survival endpoints were signiﬁ -
cantly inﬂ uenced by the treatment intensity (in 
addition to performance status and stage of dis-
ease), which clearly determined a subpopulation 
of patients (mitomycin C ≥14.1mg/m2 + bleomy-
cin ≥35mg + biological equivalent dose ≥65Gy10) 
with more favourable prognosis (Figure 2). When 
contrasting our experience with three other 
comparable series on exclusively oropharyngeal 
cancer, but with cisplatin (or carboplatin) and 
5-ﬂ uorouracil chemotherapy [19–22], the ef-
fectiveness of our unconventional drug combi-
nation appeared to be at least equivalent to the 
well established platinum-based chemotherapy 
standard (Table 1). This observation imposes 
the presumption that the mode of therapy (in-
duction vs. concomitant) is more important than 
the choice of the drugs.
Operable tumours
Between March 1997 and December 2001, 114 
patients were randomly assigned after curative 
surgery to the postoperative radiotherapy group 
(RT, 55 patients) or concomitant chemoradiother-
apy group (CRT, 59 patients). The patients were 
stratiﬁ ed according to the UICC pTNM stage, site 
of the primary tumour and presence/absence of 
high risk prognostic factors (i.e. extracapsular tu-
mour spread, perineural, lymphatic or venous in-
vasion, and residual disease) [12].
After a median follow-up time of 76 months, a sig-
niﬁ cant survival advantage was conﬁ rmed in the 
CRT arm compared to the RT arm in respect of 
5-year locoregional control (88% vs. 65%, P=0.026) 
and disease-free survival (53% vs. 33%, P=0.035), 
whereas in the case of overall survival, only a trend 
was observed (55% vs. 37%, P=0.091). After strat-
ifying the patients according to the presence or 
absence of high risk prognostic factors (extracap-
sular extension and/or residual disease), the dif-
ference between RT and CRT reached the level 
of statistical signiﬁ cance only in the patients with 
high risk factors, but not in the low risk group. 
There was no difference in the rate of occurrence 
of distant metastases between the two treatment 
groups, whereas the 5-year probability of develop-
ing a second primary malignancy was higher in 
the RT arm (34 vs. 8%, P=0.023). Even though the 
chemotherapy was not designed to act on system-
ic metastases (as the drug doses were sufﬁ cient to 
enhance the effect of irradiation), it seems possi-
ble that it acts on in situ second primary tumours 
either to cure them or delay their development. 
AuthorRef. N Treatment
FUP Outcome (%)
Remarks
(yrs.) LRC DFS OS
Calais et al.,
199919 & 200120 109
RT 70Gy + 3 cycles of: 5 53 30 nr Stages
CARBO 70mg/m2, days 1–4 III & IV
5-FU 600 mg/m2, days 1–4
Staar et al., 200121 87
IHFA RT 69.9Gy + 2 53 nr nr Inoperable
CARBO 70mg/m2, days 1–5 & 29–33 stages
5-FU 600mg/m2, days 1–5 & 29–33 III & IV
Olmi et al., 200322 64
RT 66–70Gy + 3 cycles of: 2 nr 42 51 Stages
CARBO 75mg/m2, days 1–4 T1N1 & T2N1
5-FU 1000mg/m2, days 1–4 excluded
IOL, 200618 95
RT 70Gy + 2 60 55 52 Inoperable
MITO-C 15mg/m2, day 5 5 56 51 34 stages
MITO-C 10mg/m2, day 46 III & IV
BLEO 5mg biw
Table 1. Inoperable oropharyngeal cancer: results in experimental arm of selected prospective randomized trials on concomitant 
chemoradiotherapy (see text for details).
N – number of patients, FUP – follow up, LRC – locoregional control, DFS – disease-free survival, OS – overallsurvival, RT – conventional 
radiotherapy, IHFA – intensifi ed hyperfractionated accelerated, CARBO – carboplatin, 5-FU – 5-fl uorouracil, MITO-C – mitomycin C, 
BLEO – bleomycin, biw – twice-a-week, nr – not reported, IOL – Institute of Oncology Ljubljana.
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However, the dominating causes of death in the 
CRT arm were infections and distant failures, 
which diminished the survival gain of treatment 
intensiﬁ cation by adding chemotherapy to irradi-
ation in high risk patients and resulted in a non-
signiﬁ cant log-rank P-value for overall survival be-
tween the two study arms [13].
Finally, comparing our results to those of the two 
large trials published by Bernier et al. [23] and 
Cooper et al. [24], it appears that the effectiveness 
of our chemotherapy combination is compara-
ble to the standard dose cisplatin regimen in all 
analyzed survival endpoints (Table 2).
Toxicity
As expected, acute toxic side effects to the mucosa 
and skin in the irradiated area, bone marrow tox-
icity (leukopenia, thrombocytopenia, infections) 
and weight loss were more severe and more fre-
quent, although not always statistically signiﬁ cant, 
in the CRT arm compared to the RT arm in both 
of our trials [10,12]. As the median dose of mito-
mycin C administered to our patients was close to 
that prescribed in the protocol, indicating relatively 
safe systemic toxicity proﬁ le of the drug, the dose 
of bleomycin had to be reduced in almost all rad-
ically and all postoperatively treated patients due 
to severe mucositis. Even though some selectivi-
ty could probably be achieved with mitomycin C 
due to its selective activation in a hypoxic environ-
ment, in general the incidence of grade 3 or high-
er acute toxicity did not differ signiﬁ cantly between 
our study and cisplatin-based studies [19–24]. More 
importantly, the difference in acute toxicity proﬁ les 
between various drugs seems to be more crucial 
for consideration when choosing the most appro-
priate regimen for each individual patient.
With regard to the late adverse effects of grade 
III or higher grade, no signiﬁ cant difference in 
the probability of their development was observed 
between the RT and CRT arms of our two trials 
[10,13]. The same was reported in several cispl-
atin-based studies [19–24].
Biological activity of mitomycin C-bleomycin 
chemotherapy
Analyzing the effectiveness of the mitomycin 
C-bleomycin combination, we found the dose-
response curve calculated from our clinical data 
on inoperable oropharyngeal carcinoma to be 
steeper than usual. The gamma value 50 (g50, the 
percentage increase of local control per 1% in-
crease of the total tumour dose at the steepest 
part of the curve) in our case was 2.76, whereas 
the g-values (g37 or g50) of oropharyngeal carci-
nomas reported in the literature ranging from 
0.5 to 1.6. There are several characteristics of tu-
mours and the treatment process which make – 
AuthorRef. N Treatment
FUP Outcome (RT/CRT arm,%)
Remarks
(yrs.) LRC DFS OS
Bernier et al., 200423 334
RT 54–66Gy vs. 5 69/82 36/47 40/53 Locally
RT 54–66Gy + P=0.007 P=0.04 P=0.02 advanced
CP 100mg/m2, days 1, 22, 43
Cooper et al., 200424 459
RT 60–66Gy vs. 3 67/78 36/47 47/56 N2+ and/or
RT 60–66Gy + P=0.01 P=0.04 P=0.19 ECE and/or
CP 100mg/m2, days 1, 22, 43 R1
IOL, 200713 114
RT 56–70Gy vs. 5 65/88 33/53 37/55 Stages
RT 56–66Gy + P=0.026 P=0.035 P=0.09 III & IV
MITO-C 15mg/m2 day 5
BLEO 5mg biw
Table 2. Locally advanced head and neck cancer: results of prospective randomized trials on postoperative concomitant 
chemoradiotherapy.
N – number of patients, FUP – follow up, RT – conventional radiotherapy, CRT – chemoradiotherapy, LRC –  locoregional control, 
DFS – disease-free survival, OS – overall survival, CP – cisplatin, MITO-C – mitomycin C, BLEO – bleomycin, biw – twice-a-week, 
N2+ – two or more regional lymph  involved with tumour, ECE - extracapsular extension, R1 – microscopically involved surgical margin, 
IOL – Institute of Oncology Ljubljana.
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due to their heterogeneity – the dose-response 
curve shallow. However, as mitomycin C selective-
ly kills the most radioresistant, i.e. hypoxic, frac-
tion in the tumour, the residual tumour clono-
genes become more homogeneous in terms of 
radioresponsiveness. Consequently, the steepness 
of the dose-response curve is increased. Any dis-
cussion on the contribution of bleomycin to the 
shape of the dose-response curve, based on our 
clinical data, would be only speculative [18].
The next interesting observation was related to 
the ratio in locoregional control rate between low 
and high haemoglobin groups. In our study on 
inoperable oropharyngeal carcinoma, this ratio 
was 0.84 [18], whereas in another two mitomy-
cin C trials published by Budach et al. [25] and 
Glaser et al. [26], the ratio was 0.82 and 0.93, re-
spectively. When comparing these results with oth-
er published data for head and neck carcinoma 
where other chemotherapy regimens were used 
(mainly cisplatin-based) and where the ratio was 
generally much lower, it seemed that mitomycin 
C had the potential to mask the negative effect of 
low haemoglobin level. By acting on and reduc-
ing the hypoxic part in the tumour, mitomycin 
C rendered the tumour response less dependent 
on haemoglobin concentration [18].
OTHER OPTIONS
With more comprehensive understanding of ra-
diobiological principles of radiotherapy and re-
cent developments in biological drug modelling 
and technology, more room for improvement in 
some other areas is available.
A promising upgrading of the existing concept 
of concomitant chemoradiation seems to be the 
integration of induction chemotherapy and bio-
logical agents into treatment protocols. The ra-
tionale for a sequential approach would be that 
the concomitant chemoradiotherapy would in-
ﬂ uence the locoregional control and the in-
duction chemotherapy would decrease the risk 
of distant metastases. With the proven poten-
tial for screening tumour radiosensitivity, down-
staging and decreasing the likelihood of distant 
metastatic disease [for a review see Ref. 27], in-
duction chemotherapy has already shown a sur-
vival beneﬁ t when docetaxel is incorporated in 
the regimen [28]. Taxanes in combination with 
platinum compounds are currently being tested 
as induction chemotherapy in combination with 
concurrent chemoradiation in several phase III 
clinical trials [27].
As the great majority of squamous cell carcino-
mas overexpress epidermal growth factor recep-
tor (EGFR), which has been found to be linked to 
poor outcome of treated patients [29,30], the in-
hibition of EGFR signalling is suggested as a new 
promising strategy in the treatment of head and 
neck carcinomas. The majority of efforts are fo-
cused on EGFR inhibition using small-molecule 
tyrosine kinase inhibitors and anti-EGFR mono-
clonal antibodies (e.g. cetuximab, Erbitux®). The 
most convincing evidence of anti-tumour effec-
tiveness of cetuximab in squamous cell carcino-
ma of the head and neck when added to standard 
therapy was provided by the multicentre rand-
omized phase III trial reported by Bonner et al., 
who compared radiotherapy with the combina-
tion of irradiation and concurrent cetuximab 
in patients with locoregionally advanced stage 
III or IV tumours [31]. The signiﬁ cant improve-
ment in locoregional control in favour of com-
bined treatment also resulted in a signiﬁ cant 
overall survival beneﬁ t in the experimental arm 
of the trial. Furthermore, as no overlapping tox-
icity was recorded between the irradiation and 
cetuximab, this experience initiated extensive 
research aiming to deﬁ ne the toxicity and efﬁ -
cacy of a triple combination consisting of cispla-
tin-based concomitant chemoradiotherapy and 
cetuximab [31]. The ongoing research results 
suggest that the standard dose cisplatin mono-
therapy (100 mg/m2 weeks 1 and 4) in combi-
nation with irradiation (concomitant boost ra-
diotherapy) and cetuximab is not an optimal 
combination, but warrants further investigation 
of its safety proﬁ le [32].
CONCLUSIONS
At the moment, concomitant chemoradiation 
with cisplatin-based chemotherapy is the most 
widely used way for potentiation of the locore-
gional effect of radiotherapy in high risk head and 
neck cancer patients. Recently, in the MACH-HN 
meta-analysis, the effectiveness of this regimen 
was recognized as superior to other chemother-
apy schedules. However, our clinical experience 
gained through prospective randomized stud-
ies on chemoradiation with mitomycin C and 
bleomycin showed that there was still a window 
of opportunity to achieve equivalent clinical re-
sults with other drug combinations. Furthermore, 
new developments in technology, biological drug 
modelling and better understanding of radiobio-
logical principles of radiotherapy create a prom-
ising basis for additional improvement in head 
and neck cancer management.
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